Skip to content
Review

Abstract 15680: Comparative Renal Safety and Efficacy of Baxdrostat vs Lorundrostat in Hypertensive Patients: A Systematic Review and Network Meta-Analysis

Nov 2026 · Circulation · 0 citations

Abstract

Background: Hypertension remains a major therapeutic challenge with significant morbidity, requiring novel pharmacological options. Selective aldosterone synthase inhibitors (ASIs), particularly baxdrostat and lorundrostat, offer a potent approach to blood pressure control. However, their comparative renal safety profiles across varying dosages remain inadequately defined. We conducted a systematic review and network meta-analysis (NMA) comparing renal safety and antihypertensive efficacy of these agents against placebo. Research Question:Among patients with hypertension, how do baxdrostat and lorundrostat compare with placebo and with each other in terms of antihypertensive efficacy and renal safety across different dosing regimens? Methods: PubMed, Cochrane, and Google Scholar were searched for relevant RCTs till May 15, 2026. Outcomes included ≥30% eGFR decline, absolute eGFR change, hyponatremia, hyperkalemia, hypotension, and changes in seated systolic and diastolic blood pressure (SBP and DBP). A frequentist NMA was conducted on R (version 5.4.1) using netmeta package. Odds ratios (ORs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes were used. Treatments were ranked according to P-scores. Results: Ten RCTs comprising 3475 patients were included. For ≥30% eGFR decline, baxdrostat 2mg (OR 8.77 [4.26-18.05]), baxdrostat 1mg (OR 7.06 [3.15-15.85]), and lorundrostat 100mg (OR 3.08 [1.10-8.60]) significantly increased risk vs placebo; baxdrostat 2mg ranked the least safe (P-score 6.6%). Only baxdrostat 2mg produced a significant absolute eGFR reduction (MD 7.01 mL/min/1.73m 2 [2.60-11.42]; P-score 83.3%). Significant hyperkalemia was observed with lorundrostat 100mg (OR 7.64 [1.40-41.78]) and baxdrostat 2mg (OR 4.18 [1.23-14.16]), with lorundrostat 100mg ranking worst (P-score 14.2%). For hyponatremia, only lorundrostat 100mg reached significance (OR 2.67 [1.44-4.97]; P-score 21.1%). No significant hypotension was detected across doses, though baxdrostat 2mg ranked worst (P-score 15.5%). Lorundrostat 50mg (MD –9.42 [–13.75; –5.09]; P-score 86.9%) and baxdrostat 2mg (MD –8.54 [–11.74; –5.35]; P-score 81%) demonstrated the greatest SBP reductions. For DBP, lorundrostat 50mg ranked highest (MD –6.00 [–11.12; –0.88]; P-score 88.6%). Conclusion: Baxdrostat and lorundrostat effectively reduce SBP and DBP in hypertension but impose significant dose-dependent renal risks. Lorundrostat 50mg achieves optimal efficacy while maintaining a comparatively favorable renal safety profile. In contrast, baxdrostat 2mg conferred the highest renal risk, while lorundrostat 100mg carried the greatest hyperkalemia burden. These findings underscore the need for personalized, dose-conscious ASI selection to maximize cardiovascular benefit while minimizing renal harm.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.